Cart
sales@molnova.com
Testosterone cypionate
CAS No. 58-20-8
Testosterone cypionate( —— )
Catalog No. M22379 CAS No. 58-20-8
Testosterone cypionate is Anabolic-Androgenic Steroids (AAS) which are synthetic substances that possess functions similar to testosterone.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 35 | In Stock |
|
| 50MG | Get Quote | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTestosterone cypionate
-
NoteResearch use only, not for human use.
-
Brief DescriptionTestosterone cypionate is Anabolic-Androgenic Steroids (AAS) which are synthetic substances that possess functions similar to testosterone.
-
DescriptionTestosterone cypionate is Anabolic-Androgenic Steroids (AAS) which are synthetic substances that possess functions similar to testosterone.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number58-20-8
-
Formula Weight412.61
-
Molecular FormulaC27H40O3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES[H][C@@]12CC[C@H](OC(=O)CCC3CCCC3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Ellerby, M, Bi,et al. POPULATION PHARMACOKINETIC/PHARMACODYNAMIC (PK/PD) MODELING OF DEPOT TESTOSTERONE CYPIONATE IN HEALTHY MALE SUBJECTS[J]. Clinical Pharmacology & Therapeutics, 2014.
molnova catalog
related products
-
Tafenoquine Succinat...
Tafenoquine Succinate is an 8-aminoquinoline. and is an agent of anti-malarial prophylactic.
-
FQI 1
FQI 1 is a selective late-stage SV40 factor (LSF) inhibitor with anticancer activity that exerts its antiproliferative activity by disrupting the mitotic spindle.
-
Ornipressin
Ornipressin is a vasoconstrictor, haemostatic and renal agent.
